European Urology Oncology

Slides:

Advertisements

Similar presentations

Advances in the Management of Skeletal Related Events/Bone Metastases in Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor.

Advertisements

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages (December 2015)

Volume 71, Issue 2, Pages (February 2017)

Volume 68, Issue 2, Pages (August 2015)

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.

Volume 60, Issue 2, Pages (August 2011)

Volume 58, Issue 4, Pages (October 2010)

Volume 27, Issue 4, Pages (December 2016)

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Volume 69, Issue 5, Pages (May 2016)

European Urology Oncology

Volume 65, Issue 5, Pages (May 2014)

Volume 68, Issue 2, Pages (August 2015)

Volume 68, Issue 1, Pages (July 2015)

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology Philipp.

Volume 72, Issue 5, Pages (November 2017)

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 74, Issue 1, Pages (July 2018)

A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.

Volume 65, Issue 1, Pages (January 2014)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 67, Issue 2, Pages (February 2015)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 70, Issue 5, Pages (November 2016)

Volume 66, Issue 3, Pages (September 2014)

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 5, Pages (November 2016)

Volume 73, Issue 6, Pages (June 2018)

Laurent Boccon-Gibod European Urology Supplements

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

Volume 60, Issue 6, Pages (December 2011)

Volume 73, Issue 5, Pages (May 2018)

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Volume 67, Issue 1, Pages (January 2015)

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Volume 71, Issue 4, Pages (April 2017)

Volume 75, Issue 3, Pages (March 2019)

European Urology Oncology

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 69, Issue 5, Pages (May 2016)

European Urology Oncology

Axel Heidenreich European Urology Supplements

European Urology Oncology

Highlighting Unmet Needs: Real Patients, Difficult Choices

European Urology Oncology

European Urology Oncology

Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at.

European Urology Oncology

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

European Urology Oncology

European Urology Oncology

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

European Urology Oncology Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration- resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, Sylvestre Le Moulec, Umberto Basso, Alison Birtle, Alastair Thomson, Michael Krainer, Aline Guillot, Ugo De Giorgi, Ali Hasbini, Gedske Daugaard, Amit Bahl, Simon Chowdhury, Orazio Caffo, Philippe Beuzeboc, Dominique Spaeth, Jean-Christophe Eymard, Aude Fléchon, Jérôme Alexandre, Carole Helissey, Mohamed Butt, Frank Priou, Éric Lechevallier, Jean-Laurent Deville, Marine Gross Goupil, Rafael Morales, Antoine Thiery-Vuillemin, Tatiana Gavrikova, Philippe Barthelemy, Avishay Sella, Karim Fizazi, Giulia Baciarello, Jean-Marc Fererro, Brigitte Laguerre, Benjamin Verret, Sophie Hans, Stéphane Oudard European Urology Oncology DOI: 10.1016/j.euo.2018.05.009 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Selection of patients for inclusion in the study. Data for patients treated with docetaxel, cabazitaxel, and one next-generation androgen receptor–targeted therapy (ART; abiraterone acetate or enzalutamide) between November 2012 and October 2016 were retrospectively collected. European Urology Oncology DOI: (10.1016/j.euo.2018.05.009) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer according to treatment sequence. Group 1: patients received DOC before CABA and then ART; group 2: patients received DOC before ART and then CABA; group 3: patients received ART before DOC and then CABA. ART=novel androgen receptor–targeted therapy (abiraterone acetate or enzalutamide); CABA=cabazitaxel; DOC=docetaxel; PSA 50=decrease in PSA from baseline of ≥50%. European Urology Oncology DOI: (10.1016/j.euo.2018.05.009) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Overall survival from sequence initiation. ART=next-generation androgen receptor targeted therapy; C=cabazitaxel; D=docetaxel. European Urology Oncology DOI: (10.1016/j.euo.2018.05.009) Copyright © 2018 European Association of Urology Terms and Conditions